Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease
Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.
EP: 1.Factors for Consideration When Choosing a Treatment for Patients With CLL
EP: 2.The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents
EP: 3.BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023
EP: 4.Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL
EP: 5.The Evolving Treatment Landscape in Relapsed/Refractory CLL
EP: 6.Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
